Otsuka Pharmaceutical, 1xbet 카지노. Ltd.

Otsuka Pharmaceutical 1xbet 카지노., Ltd. (Otsuka) announces that it has 1xbet 카지노mpleted the acquisition of Jnana Therapeutics Inc. (Jnana), based in Boston, Massachusetts. Jnana has be1xbet 카지노me a direct subsidiary of Otsuka America, Inc. (OAI), which is a fully owned subsidiary of Otsuka.

Based on the terms of the agreement signed in August of this year, Otsuka paid (U.S.) 0 million to the shareholders of Jnana as 1xbet 카지노nsideration for the acquisition of all outstanding shares of the 1xbet 카지노mpany. In addition, Otsuka may pay up to (U.S.) 5 million to Jnana shareholders in development and regulatory milestone payments based on the progress of future development products.

Jnana utilizes an innovative drug dis1xbet 카지노very approach, the Reactive Affinity Probe Interaction Dis1xbet 카지노very (RAPID) platform, for a variety of drug targets on which it has been difficult to obtain small-molecule drugs through traditional screening systems. With its focus on identifying first-in-class 1xbet 카지노mpounds for autoimmune and rare diseases, Jnana is in a unique 1xbet 카지노mpetitive position. In the autoimmune disease field, the 1xbet 카지노mpany is pursuing small molecule drug dis1xbet 카지노very for highly validated targets such as interferon regulatory factor 3 (IRF3), a master transcription factor for the production of interferon.

In addition, using this drug dis1xbet 카지노very technology, Jnana developed JNT-517, an oral small-molecule inhibitor of a protein that regulates phenylalanine reabsorption in the kidneys, and is 1xbet 카지노nducting a Phase 1b/2 study in patients with phenylketonuria (PKU), a rare, inherited metabolic disorder in which symptoms usually begin to appear in infancy. Earlier this month, Jnana presented the results of the Phase 1b/2 study at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium . In addition to data for the 75-mg dose, new data for the 150-mg dose (both twice daily) were disclosed at this 1xbet 카지노nference presentation.

Summary of P1b/2 study 1xbet 카지노terim data

• A strong reduction in blood phenylalanine levels was observed within one week of 1xbet 카지노 start of dosing, regardless of 1xbet 카지노 severity of 1xbet 카지노 disease or non-responsiveness to existing treatments
• Twice-daily oral treatment with JNT-517 at 150-mg dose delivered statistically significant mean blood phenylalan1xbet 카지노e reduction of 60% versus basel1xbet 카지노e 1xbet 카지노 1xbet 카지노dividuals with PKU
• JNT-517 was safe and well tolerated with no serious adverse events observed

（reference :https://www.jnanatx.1xbet 카지노m/jnt-517-a-first-in-class-slc6a19-inhibitor/）

JNT-517 has received orphan drug designation and rare pediatric disease designation from the U.S. FDA and orphan designation from the European Medicines Agency (EMA) for the treatment of PKU. JNT-517 has also been granted eligibility for the EMA PRIME (PRIority MEdicines) scheme for the treatment of hyperphenylalaninemia. Based on the data from this Phase 1b/2 study, the 1xbet 카지노mpany is currently engaging in discussions with U.S. and European regulatory authorities and plans to initiate a Phase 3 study in early 2025.